How Is Treatment Response Measured in Kidney Amyloidosis? Protein Loss, Swelling, Function

The urine jug goes in the fridge, next to the milk. For twenty-four hours a woman in her sixties collects every drop, feeling faintly ridiculous, because this plastic container will tell her care team something her ankles cannot: whether the treatment she began four months ago is starting to work on her kidneys. Her latest blood tests already look better. Her shoes still feel tight by evening.

That gap between good news in the blood and slow news in the kidney is the central puzzle of kidney amyloidosis treatment response. Amyloidosis is a condition in which misfolded proteins clump into fibers and lodge in organs; when those fibers settle in the kidney’s filters, protein that should stay in the blood leaks into the urine. Treatment aims to cut off the supply of misfolding protein. The kidney then has to do its own slow work.

This article explains what is measured, why each measure matters, how the formal response criteria used in research translate to a clinic visit, and what a realistic timeline looks like.

Why kidney amyloidosis treatment response is measured in three languages at once

Three different things are happening in a person with kidney amyloidosis, and each needs its own instrument. First, somewhere in the body, a protein is being produced in a form that misfolds. In AL amyloidosis, the most common type affecting the kidney, that protein is a fragment of an antibody called a light chain, made by abnormal plasma cells in the bone marrow. In AA amyloidosis, it is serum amyloid A, a protein the liver pours out during long-standing inflammation. Second, those misfolded proteins have already been deposited as amyloid in the glomeruli, the microscopic sieves that filter blood into urine. Third, the damaged sieves are leaking albumin and other proteins, which drives swelling and can gradually wear down kidney function.

Treatment response is therefore assessed on all three levels. Blood tests look at the supply: are the light chains or inflammatory markers falling? Urine tests look at the leak: is protein loss shrinking? Kidney function tests look at the filter itself: is the estimated glomerular filtration rate holding steady, improving or slipping? The Mayo Clinic describes this layered approach, in which treatment targets the source while the organs are monitored for recovery (Mayo Clinic).

Why not simply ask how the patient feels? Because feelings arrive late and leave late. Swelling can persist for months after protein leak starts to improve, and it can be masked or worsened by fluid-removing medicines, salt intake and heart involvement. A person can be responding well on paper while still needing two pillows to sleep. The reverse is also true. That is why clinicians resist judging kidney amyloidosis treatment response from a single number, and why the rest of this article takes each measurement in turn.

What treatment is actually aiming at, and what it cannot do directly

Nothing currently used in routine care pulls existing amyloid out of a kidney. Treatment works upstream. In AL amyloidosis, the medicines are borrowed from the treatment of plasma cell cancers: combinations that may include a proteasome inhibitor, an anti-CD38 monoclonal antibody, an alkylating agent and a corticosteroid, and for selected people high-dose chemotherapy followed by a transplant of their own stem cells. The Mayo Clinic and MedlinePlus both describe these as the standard categories of AL therapy, chosen and adjusted by a hematologist based on organ involvement and fitness (Mayo Clinic; MedlinePlus). Which combination, and whether a transplant is appropriate, is a decision for the treating team.

The immediate goal is a hematologic response: a fall in the abnormal free light chains in the blood, measured by a serum free light chain test and by immunofixation, which detects abnormal antibody proteins. Hematologists grade this as partial, very good partial or complete depending on how far the abnormal light chain has fallen relative to its normal partner.

Only once the supply drops can the kidney begin to clear deposits and repair its filters. That is the organ response, and it is measured separately. A person can achieve a deep hematologic response and still show no renal change for many months. Clinicians expect that lag; it does not mean the therapy has failed.

In AA amyloidosis the logic is identical but the target is inflammation. Controlling the underlying condition, whether rheumatoid arthritis, an inherited fever syndrome or a chronic infection, lowers serum amyloid A and lets deposition slow or stop (NIDDK). In the rarer hereditary and transthyretin forms that involve the kidney, the strategy is again to reduce or stabilize the precursor protein.

Alongside this runs supportive treatment: salt restriction, diuretics to manage fluid, and sometimes blood-pressure medicines of the type that also reduce protein leak. These ease symptoms and protect the kidney, but they are not measured as “response” to the disease itself.

Protein loss: why the 24-hour urine collection is still the main yardstick

Proteinuria means protein in the urine. A healthy glomerulus lets water and small waste molecules through while holding back albumin, the main blood protein. Amyloid fibers stiffen and thicken the filter walls so albumin escapes. Grams of it, in heavy cases. The 24-hour urine protein is the most direct readout of that leak, which is why it anchors the formal response criteria used in AL amyloidosis research (Palladini and colleagues, Blood; PubMed).

People often ask whether a single spot sample would do. Spot urine protein-to-creatinine ratios are convenient and are used for screening and interim checks, but protein excretion varies through the day with posture, fluid intake and activity. For decisions about whether kidney amyloidosis treatment response has occurred, most specialist teams still want the full collection, at least at key time points (Mayo Clinic). The inconvenience is real; the data are worth it.

What are clinicians looking for? Two things: the direction and the size of the change from baseline. A modest reduction of a few percent sits inside normal day-to-day variation. A fall of roughly a third or more, sustained across repeated measurements, is treated as meaningful in the trial criteria discussed in the next section. Falling below roughly half a gram a day is the marker of a very deep response, close to what a healthy kidney would excrete.

Proteinuria matters for reasons beyond scorekeeping. Heavy protein loss lowers blood albumin, which pulls fluid out of blood vessels into tissues and produces swelling. It raises cholesterol. It increases the risk of blood clots, because the kidney also leaks proteins that normally keep clotting in check. Reducing the leak therefore improves several things at once. When a urine result improves, the effects on legs, energy and cholesterol usually follow, but on a delay measured in months rather than weeks.

Renal response criteria in amyloidosis: what the trial definitions actually say

Because early trials in AL amyloidosis used inconsistent definitions, an international group led by Palladini published criteria in Blood that many centers now use in clinic as well as research (PubMed). They defined a renal response as a reduction in 24-hour urine protein of at least 30 percent from baseline, or a fall to below 0.5 grams per day, provided kidney function had not deteriorated substantially at the same time. Renal progression was defined as a decline in estimated glomerular filtration rate of 25 percent or more from baseline. The assessment point in that study was six months after starting treatment, with changes at three months already carrying information about the eventual outcome.

The same paper introduced a renal staging system built on two thresholds at diagnosis: proteinuria above 5 grams per day and an eGFR below 50. Neither threshold crossed places a person in stage I; one places them in stage II; both, stage III. The stages predicted the likelihood of needing dialysis over the following years, with higher stages carrying greater risk (PubMed). Exact figures vary between cohorts and are best discussed with your own team, who can place your results in the context of your age, blood pressure and heart involvement.

Measure	What it tracks	Response signal (trial criteria)	Progression signal
24-hour urine protein	Filter leak	Fall of 30% or more, or below 0.5 g/day, without eGFR worsening	Rising protein with falling eGFR
eGFR / creatinine	Filtering capacity	Stable or improving	Fall of 25% or more from baseline
Serum free light chains (AL)	Supply of misfolding protein	Partial to complete hematologic response	Rising abnormal light chain
Weight, swelling, albumin	Fluid balance and nutrition	Gradual improvement, often lagging	Rapid weight gain, worsening edema

Later authors have proposed graded versions with more categories, reflecting the observation that a very deep drop in proteinuria carries more prognostic weight than a borderline one. Your team may quote either framework; the underlying measurements are the same.

Swelling: what your ankles can and cannot tell you

Edema, the medical word for swelling from trapped fluid, is often what brought a person to the doctor in the first place. It is also the measure patients trust most, because it is the one they can see. The trouble is that swelling responds to at least four things at once: how much protein the kidney is leaking, how much salt and fluid are being taken in, how much the diuretic is removing, and whether the heart, which can also harbor amyloid, is pumping well enough to move fluid along. Untangling those takes more than a glance at the ankles.

Clinicians therefore convert swelling into numbers. Daily morning weight on the same scale, after emptying the bladder and before breakfast, is the most useful home measure; a steady downward drift over weeks suggests fluid is leaving, while a jump over a few days usually means fluid is accumulating. Blood albumin, measured at each visit, is the other half of the picture. As protein leak falls, albumin slowly recovers, and swelling eases because fluid is drawn back into the bloodstream. NIDDK describes this relationship between protein loss, low albumin and edema in nephrotic syndrome (NIDDK).

Two cautions. First, swelling can worsen temporarily early in treatment even when things are going well, because corticosteroids in AL regimens cause salt and water retention, and because albumin takes time to rebuild. Second, swelling can improve for the wrong reason, for example when a diuretic dose is increased, which does nothing for the underlying disease. Diuretic adjustments are common and are made by the treating team, sometimes weekly in the early phase; never alter them on your own.

In short, swelling is a real and legitimate outcome, but it is a lagging and noisy one. When a clinician reassures you that the urine protein is falling despite persistent puffiness, they are reading the earlier signal.

Kidney function: eGFR, creatinine and why "stable" is often a win

Creatinine is a waste product of muscle that healthy kidneys clear efficiently; when filtering slows, it accumulates in the blood. The estimated glomerular filtration rate, or eGFR, converts that creatinine level into an estimate of how many milliliters of blood the kidneys filter each minute, adjusted for age and sex. MedlinePlus notes that an eGFR of 60 or above is generally considered normal, while a value below 15 indicates kidney failure requiring discussion of dialysis or transplant (MedlinePlus).

In kidney amyloidosis, eGFR plays a different role from proteinuria. Proteinuria is the measure that usually improves with successful treatment. eGFR is the measure that clinicians mainly hope to protect. Scar tissue does not become filter again, so a kidney whose function has already declined may not recover it even when the disease is fully controlled. For that reason, an unchanged eGFR after a year of therapy is frequently regarded as a good result, particularly if proteinuria has fallen. The renal response criteria formalize this: a response requires that eGFR has not dropped by 25 percent or more (PubMed).

Several things can move eGFR without reflecting disease activity. Dehydration from vigorous diuretic use, certain antibiotics and anti-inflammatory painkillers, contrast dye for scans, and even a large protein meal before the blood draw can nudge creatinine up. Weight loss from illness reduces muscle mass and can make eGFR look falsely reassuring. Clinicians look at the trend across several measurements rather than any single value, and they interpret dips in the context of medication changes.

Some centers add cystatin C, a second filtration marker less affected by muscle mass, or measure albumin excretion alongside total protein. These refinements matter most when the eGFR is near a decision threshold, for example when planning for the possibility of dialysis. The principle is constant: protect what remains, and read function in trend, not snapshot.

Who is usually monitored this way, and who is asked to wait

Response monitoring on the schedule described here is standard for anyone with AL amyloidosis and kidney involvement who is receiving plasma-cell-directed therapy. Urine and blood are typically checked every one to three months in the first year, with light chains often measured more frequently than urine protein because they change faster (Mayo Clinic). People undergoing stem cell transplantation are assessed at set intervals afterward, since the hematologic response can take months to reach its depth.

People with AA amyloidosis are monitored somewhat differently. Serum amyloid A or C-reactive protein, both markers of inflammation, become the primary supply measure, and urine protein and eGFR are checked at intervals that reflect how quickly the underlying condition is being brought under control (NIDDK). Because AA deposition tends to be slower, follow-up gaps may be longer once inflammation is suppressed.

Some people are asked to wait or watch rather than treat. A person whose kidney biopsy shows amyloid but whose light chain levels are only marginally abnormal, with minimal proteinuria and normal eGFR, may be observed closely rather than started on therapy straight away, because the risks of treatment must be weighed against a slowly moving disease. Someone with advanced kidney failure who is already on dialysis still benefits from controlling light chains to protect the heart and other organs, but renal response criteria no longer apply to kidneys that have stopped filtering; the discussion shifts to dialysis quality and eligibility for kidney transplantation, which usually requires a sustained hematologic response first.

People too frail for intensive regimens are offered gentler combinations, and their response is still tracked with the same measurements, just with more tolerance for gradual change. None of these pathways is a lesser standard of care; they reflect matching the intensity of treatment and monitoring to the person in front of the clinician. Where you fit is a conversation with your hematologist and nephrologist together.

What the first weeks and months of treatment usually look like

Expect the blood to move first. In AL amyloidosis, serum free light chains often begin to fall within the first cycle or two of therapy, and hematologists commonly reassess after two to three months to decide whether the regimen is working or should change (Mayo Clinic). This is the period when treatment decisions are most active, and it is entirely driven by the supply measure, not by the kidney.

The kidney is quieter. Urine protein may not change at all in the first three months; it may even rise slightly if corticosteroids are causing fluid retention or if blood pressure has shifted. The Palladini criteria were built around a six-month assessment precisely because earlier readings are unreliable, although the same study found that early trends at three months already carried information (PubMed). Between visits, the most useful things a person can do are weigh themselves each morning, keep a simple log, and follow the salt guidance they have been given.

By six to twelve months, most people who are going to show a renal response have started to. Proteinuria falls, albumin climbs, and swelling recedes, in that order. Diuretic needs often decrease and the team may step them down; do not do this yourself, as too much fluid removal can strain kidneys already under stress. Some people continue to improve well into the second year. Renal responses in AL amyloidosis are known to deepen slowly, and a modest fall at six months can become a much larger one by eighteen.

Side effects run on their own clock. Nerve tingling from some drug classes, fatigue, infection risk from lowered immunity and fluid shifts from steroids are all discussed with the prescribing team at each visit. Reporting them promptly matters, because dose adjustments are often possible without sacrificing response. Throughout, the pattern to hold in mind is simple: blood in weeks, urine in months, ankles last of all.

How quickly does amyloidosis progress, and how fast can the kidney recover?

Untreated AL amyloidosis tends to progress faster than AA amyloidosis, because a clone of plasma cells can produce misfolding light chains continuously and in quantity, whereas serum amyloid A rises and falls with inflammation. The NHS notes that AL amyloidosis can be life-threatening if untreated and that early diagnosis and treatment help protect organs (NHS). For the kidney specifically, the speed of decline depends on how much protein is leaking and how much filtering capacity has already been lost, which is exactly what the renal staging system captures (PubMed). A person with heavy proteinuria and a reduced eGFR at diagnosis is at greater risk of reaching dialysis within a few years than a person with a modest leak and preserved function.

Recovery runs on a slower gear than decline. Even after light chains are suppressed, amyloid already in the glomeruli must be cleared by the body’s own scavenging systems, and the filter walls must remodel. That is why renal responses are assessed at six months and often continue improving beyond a year. Some kidneys with substantial scarring never regain filtering capacity but still benefit enormously from having the leak plugged, because continued proteinuria itself accelerates loss of function.

People also ask whether the disease can come back. Relapse in AL amyloidosis means the plasma cell clone becomes active again and light chains rise; the earliest sign is almost always in the blood, months before urine protein climbs. This is the main reason lifelong monitoring of light chains continues even after a complete hematologic response. In AA amyloidosis, a flare of the underlying inflammatory condition can restart deposition, so keeping that condition controlled is the long-term strategy.

What none of this supports is a fixed calendar. Progression and recovery vary widely between people, and the honest answer to “how quickly” is: it depends on type, stage and how deeply the supply is controlled, all of which your team is measuring.

Kidney amyloidosis prognosis: what shapes it and what the numbers mean

Prognosis in kidney amyloidosis is shaped by three questions. What type is it? How much has the kidney already lost? And is the heart involved? Heart involvement dominates survival in AL amyloidosis, which is why staging systems for the disease as a whole rest on cardiac blood markers rather than kidney tests (Mayo Clinic). Kidney-specific prognosis, meaning the risk of eventually needing dialysis, is shaped by proteinuria and eGFR at diagnosis and, above all, by whether treatment achieves a hematologic response followed by a renal one (PubMed).

This has practical consequences for how to read your own results. A deep hematologic response is the strongest predictor that the kidney will do well; a renal response, when it arrives, is an even more direct sign. Stable eGFR over the first year is reassuring even without a dramatic fall in proteinuria. Conversely, rising proteinuria together with falling eGFR is the pattern that prompts teams to change therapy.

Type matters too. AA amyloidosis of the kidney, when the underlying inflammation is brought fully under control, has a course that can plateau for years (NIDDK). Hereditary forms vary by the protein involved. Transthyretin amyloidosis rarely causes heavy proteinuria, so kidney prognosis is seldom the main concern there.

Many people search for published survival percentages. The figures that exist come from research cohorts collected over specific periods, with treatment regimens that have since changed, and they describe groups rather than individuals. A percentage from a study is not a forecast for you. Your team can tell you which stage your kidney measurements correspond to, how your light chains have moved, and what that has meant for people with a similar pattern under current treatment. That conversation, revisited as results come in, is a better guide than any single number found online.

AA amyloidosis and other types: measuring response when the cause is inflammation

In AA amyloidosis the misfolding protein is serum amyloid A, made by the liver whenever the body is inflamed. Long-standing rheumatoid arthritis, inflammatory bowel disease, chronic infections such as tuberculosis or osteomyelitis, and inherited periodic fever syndromes are the classic drivers (NIDDK). The kidney is the organ most often affected. Treatment response is measured almost the same way as in AL, with one substitution: instead of free light chains, the supply marker is serum amyloid A itself, or C-reactive protein as a more widely available proxy.

The logic follows. If inflammation is controlled and serum amyloid A stays consistently low, deposition slows or stops, and proteinuria has the chance to fall. If inflammation flickers on and off, deposition continues between flares. Rheumatologists and nephrologists therefore aim for sustained suppression rather than occasional good readings, using whatever treats the underlying condition, which may include disease-modifying medicines or biologic therapies chosen by the specialist responsible for that condition. In familial Mediterranean fever, long-term anti-inflammatory prophylaxis is the established approach.

Renal measurements are identical: 24-hour urine protein, eGFR, albumin and weight. Because AA disease tends to move more slowly, meaningful change in the kidney may take longer to declare itself, and follow-up intervals are often stretched once inflammation is quiet.

Other forms are rarer. Hereditary amyloidosis caused by variants in fibrinogen, apolipoprotein or lysozyme can present primarily in the kidney and is diagnosed by genetic testing after the amyloid type is confirmed on biopsy. Response monitoring focuses on eGFR because the precursor protein often cannot be lowered with medicines; liver transplantation has been used in some fibrinogen cases. Transthyretin amyloidosis mainly affects the heart and nerves; kidney monitoring there is about protecting function while stabilizers or gene-silencing therapies reduce the precursor. Whatever the type, the first step is always accurate typing of the deposit, because measuring response to the wrong target helps no one.

What people often get wrong about kidney amyloidosis treatment response

“My swelling is gone, so the amyloid is gone.” Swelling improves when fluid balance improves, which can happen because of diuretics alone. The disease is judged by urine protein, kidney function and, in AL, light chains, not by trouser fit.

“My blood tests are normal, so my kidney is fixed.” A hematologic response stops the supply. The kidney’s own repair follows on a delay of months, and some scarring is permanent. Good blood results are necessary for kidney recovery but are not the same thing.

“The 5 5 5 rule tells me my stage.” There is no “5 5 5 rule” in any amyloidosis guideline or consensus criteria. The phrase circulates online and probably conflates the renal staging threshold of 5 grams of proteinuria per day with other numbers (PubMed). If someone quotes it, ask them to show you the source; your team will use published staging systems instead.

“A celebrity had this, so I know how it goes.” Several public figures have spoken about living with different types of amyloidosis, which has helped awareness. Their course tells you about their type, stage and treatment, not yours. Amyloidosis is a family of conditions, not one disease.

“I need another kidney biopsy to see if it’s working.” Repeat biopsies are rarely done for response assessment. Amyloid clears slowly and unevenly, and a repeat sample carries bleeding risk without changing management. Urine and blood tests do the job (Mayo Clinic).

“Less protein in my diet means less protein in my urine.” The leak comes from damaged filters, not from what you eat. Very low protein diets can cause malnutrition in people already losing protein. Dietary advice should come from a kidney dietitian working with your team.

“If my eGFR hasn’t improved, treatment failed.” Stable function while proteinuria falls is one of the most common patterns of genuine success. Recovery of eGFR is a bonus, not the benchmark.

Questions to ask your care team

Arriving at a clinic visit with specific questions turns a stream of numbers into a conversation you can follow. These are the ones that tend to matter most for tracking kidney amyloidosis treatment response.

• Which type of amyloidosis do I have, and has the deposit been typed by a method your team considers definitive?
• What were my baseline 24-hour urine protein and eGFR, and which renal stage did they correspond to?
• What is my current hematologic response category, and what depth are you aiming for before you expect the kidney to change?
• How often will you repeat urine protein, eGFR and light chains during the first year, and which visits are the formal assessment points?
• How much change in urine protein would you consider a real response rather than normal variation for me?
• What pattern of results would make you consider changing treatment, and what would make you consider stopping?
• Is my heart involved, and how does that affect the way you read my fluid balance and diuretic needs?
• What should I record at home between visits, and how should I send you those readings?
• Which medicines, supplements or over-the-counter painkillers should I avoid because they could affect kidney function or interact with my treatment?
• If my kidney function continues to fall, at what point would we start discussing dialysis planning or transplant eligibility, and what would need to be true about my light chains first?
• Who do I call between visits with a concern, and what counts as urgent?

Write the answers down or ask permission to record the conversation. Many people find it useful to keep a single page with their baseline numbers and each subsequent result, so that the trend, the thing that actually matters, is visible at a glance. Bring the page to every visit, including those with other specialists, so the picture stays joined up.

When to call your doctor

Most changes during treatment unfold over weeks and can wait for the next scheduled visit. Some cannot. Contact your care team the same day, or use urgent services if you cannot reach them, for any of the following.

• A sudden increase in swelling or a rapid weight gain over two or three days, especially with breathlessness lying flat or at rest, which can signal fluid overload or heart involvement.
• Passing much less urine than usual, or none, over a day, which may indicate acute kidney injury or severe dehydration from diuretics.
• A swollen, painful or warm calf, or sudden chest pain and breathlessness, because heavy protein loss raises the risk of blood clots in the leg or lung.
• Fever, shaking chills or feeling generally unwell while on plasma-cell-directed therapy, since these medicines lower immunity and infection can escalate quickly.
• Fainting, near-fainting or persistent dizziness on standing, which can reflect low blood pressure from fluid shifts, autonomic nerve involvement or medication effects.
• New confusion, severe headache, or unusual bleeding or bruising.
• Sudden numbness, weakness or tingling that is new or rapidly worsening.

These signs do not mean treatment has failed. They mean something needs assessing now rather than at the next visit, and often the fix is a medication adjustment or a short course of supportive care. Between appointments, keep your team’s contact number where you can find it, and tell any other clinician you see, including in an emergency department, that you have amyloidosis and which medicines you take. MedlinePlus and the NHS both stress prompt reporting of new symptoms during amyloidosis treatment (MedlinePlus; NHS). When in doubt, call; your team would far rather hear from you about something that turns out to be minor than learn afterward about something that was not.

Frequently asked questions

What is the prognosis for patients with amyloidosis in the kidney?

Kidney prognosis depends on the type of amyloidosis, how much proteinuria and filtering capacity were present at diagnosis, and whether treatment achieves a sustained response in the supply protein. In AL amyloidosis, heart involvement affects overall survival more than kidney involvement does. Published survival percentages come from research cohorts treated in earlier eras and describe groups, not individuals, so your own team’s reading of your stage and response trend is a better guide.

What is the 5 5 5 rule for amyloidosis?

No such rule exists in published guidelines or consensus criteria. The phrase circulates online and likely merges the renal staging threshold of 5 grams of urine protein per day with unrelated figures. Formal staging for kidney involvement in AL amyloidosis uses two thresholds: proteinuria above 5 grams per day and eGFR below 50. If someone quotes a 5 5 5 rule, ask for the source and check it against what your care team uses.

How quickly does amyloidosis progress?

It varies widely by type and stage. Untreated AL amyloidosis tends to progress over months because plasma cells keep producing misfolding light chains, and the NHS notes it can be life-threatening without treatment. AA amyloidosis usually moves more slowly and tracks with the underlying inflammation. For the kidney, heavier proteinuria and lower eGFR at diagnosis predict faster decline toward dialysis, which is why early typing and treatment matter.

Why is my amyloidosis proteinuria still high after treatment when my blood tests are better?

Because the kidney responds on a delay. Treatment lowers the supply of misfolding protein, which shows in the blood within weeks, but amyloid already deposited in the filters must be cleared and the filter walls remodeled before the leak shrinks. Renal response is formally assessed at around six months and often deepens over the following year. Persistent proteinuria at three months does not by itself mean treatment has failed.

What celebrity has amyloidosis, and does their story apply to me?

Several public figures have spoken openly about living with different types of amyloidosis, and their openness has raised awareness of a condition that is often diagnosed late. Their experience reflects their particular type, organs involved, stage and treatment, none of which may match yours. Amyloidosis is a family of related conditions rather than one disease, so a public account is a reason for hope and curiosity, not a template for your own course.

Do I need a repeat kidney biopsy to see whether treatment is working?

Usually not. Response is judged from urine protein, kidney function tests and, in AL amyloidosis, serum free light chains. Amyloid clears from tissue slowly and unevenly, so a repeat biopsy would rarely change management and carries a bleeding risk. Biopsy is important at diagnosis to confirm and type the deposit. Your team may consider another sample only if results are contradictory or a second process in the kidney is suspected.

Can kidney function recover once amyloid is controlled?

Sometimes partially, but scarred filter tissue does not regenerate, so the realistic goal is usually to stabilize eGFR while proteinuria falls. People whose kidney function was still well preserved at diagnosis have the best chance of holding it. In the trial criteria, a renal response requires that eGFR has not declined by 25 percent or more, reflecting the view that protecting function is as important as reducing the protein leak.

How often will my urine protein and eGFR be checked?

Typically every one to three months during the first year of AL treatment, with free light chains measured more often because they change faster, and formal renal assessment points at around six and twelve months. Intervals usually lengthen once a stable response is established. In AA amyloidosis, checks are timed to how quickly inflammation is being controlled. Your team sets the schedule based on your stage and treatment.

Does eating less protein reduce the protein in my urine?

No. The protein in your urine escapes through damaged filters and is not driven by dietary intake. Very low protein diets can cause malnutrition in people who are already losing albumin. Dietary advice in kidney amyloidosis focuses on limiting salt to control swelling and maintaining adequate nutrition, and it should come from a kidney dietitian working alongside your medical team rather than from general online guidance.

What does relapse look like, and would I notice it first in my kidneys?

In AL amyloidosis, relapse means the plasma cell clone becomes active again, and the earliest sign is almost always rising free light chains in the blood, often months before urine protein increases or swelling returns. That is why light chain monitoring continues long term even after a complete response. In AA amyloidosis, a flare of the underlying inflammatory condition is the warning sign, so keeping that condition controlled is central.

References

• MedlinePlus: Amyloidosis
• NIH NIDDK: Amyloidosis and Kidney Disease
• MedlinePlus: Glomerular Filtration Rate (GFR) Test
• NHS: Amyloidosis

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.